| 11120346 |
Method and descriptors for comparing object-induced information flows in a plurality of interaction networks |
— |
2021-09-14 |
|
| 10242091 |
Method of knowledge extraction through data mining |
William T. Loging, Robert A. Volkmann |
2019-03-26 |
|
| 10072018 |
Compounds for treatment of pain |
Robert A. Volkmann, Anthony Marfat, Peter Cornelius, Panayiotis Zagouras, Fredrick Raymond Nelson |
2018-09-11 |
|
| 10017529 |
Metformin derivatives |
Robert A. Volkmann |
2018-07-10 |
|
| 9487531 |
Compounds for treatment of pain |
Robert A. Volkmann, Anthony Marfat, Peter Cornelius, Panayiotis Zagouras, Frederick Nelson |
2016-11-08 |
|
| 8686043 |
Heterocyclic sulfonamides, uses and pharmaceutical compositions thereof |
Randall J. Gallaschun, Christopher John O'Donnell, Jacob Bradley Schwarz, Barbara E. Segelstein |
2014-04-01 |
$235,129,000 |
| 8278457 |
Heterocyclic sulfonamides, uses and pharmaceutical compositions thereof |
Randall J. Gallaschun, Christopher John O'Donnell, Jacob Bradley Schwarz, Barbara E. Segelstein |
2012-10-02 |
$211,962,000 |
| 7220753 |
2,7-substituted octahydro-1H-pyrido[1,2-a]pyrazine derivatives as ligands for serotonin receptors |
Kishor A. Desai, Mark Sanner |
2007-05-22 |
$210,338,000 |
| 7056922 |
Acylamino cyclopropane derivatives |
Anthony R. Reinhold |
2006-06-06 |
$125,956,000 |
| 6664258 |
Spirocyclic dopamine receptor subtype ligands |
Todd W. Butler |
2003-12-16 |
$278,129,000 |
| 6552015 |
Azabicycloalkane derivatives and therapeutic uses thereof |
Todd W. Butler, Randall J. Gallaschun |
2003-04-22 |
$591,897,000 |
| 6531468 |
Diazabicyclooctane derivatives and therapeutic uses thereof |
Randall J. Gallaschun |
2003-03-11 |
$286,514,000 |
| 6521630 |
Tetrahydroquinazoline-2,4-diones and therapeutic uses thereof |
Todd W. Butler, Randall J. Gallaschun, John Ragan, Brian Patrick Jones |
2003-02-18 |
$293,757,000 |
| 6372762 |
Substituted bicyclic derivatives for treating central nervous system disorders |
Todd W. Butler |
2002-04-16 |
$246,300,000 |
| 6231833 |
2,7-substituted octahydro-1H-pyrido[1,2-A]pyrazine derivatives as ligands for serotonin receptors |
Kishor A. Desai, Mark Sanner |
2001-05-15 |
$572,634,000 |
| 5889010 |
Benzimidazole derivatives having dopaminergic activity |
William Stephen Faraci, Brian Thomas O'Neill, Mark Sanner, Stevin Zorn |
1999-03-30 |
$332,124,000 |
| 5883094 |
Benzimidazolone derivatives with central dopaminergic activity |
Brian Thomas O'Neill, William Stephen Faraci, Mark Sanner, Stevin Zorn |
1999-03-16 |
$342,327,000 |
| 5852031 |
2,7-substituted octahydro-1H-pyrido1,2-a!pyrazine derivatives |
Kishor A. Desai, Mark Sanner |
1998-12-22 |
$228,111,000 |
| 5583137 |
Heterocyclic compounds for enhancing antitumor activity |
Jotham Wadsworth Coe, Takushi Kaneko, Eric R. Larson |
1996-12-10 |
$96,360,000 |
| 5536722 |
Triazine derivatives for enhancing antitumor activity |
Jotham Wadsworth Coe, Takushi Kaneko, Eric R. Larson |
1996-07-16 |
$93,063,000 |
| 5491234 |
Pyrimidine derivatives for enhancing antitumor activity |
Jotham Wadsworth Coe, Takushi Kaneko, Eric R. Larson |
1996-02-13 |
$259,633,000 |
| 5444062 |
Quinazolines derivatives for enhancing antitumor activity |
Jotham Wadsworth Coe, Takushi Kaneko, Eric R. Larson |
1995-08-22 |
$37,394,000 |
| 4970318 |
Aromatic and heterocyclic carboxamide derivatives as antineoplastic agents |
Rodney C. Schnur |
1990-11-13 |
$70,851,000 |
| 4948891 |
Benzamide protease inhibitors |
Rodney C. Schnur |
1990-08-14 |
$15,297,000 |
| 4948901 |
Benzamide protease inhibitors |
Rodney C. Schnur |
1990-08-14 |
$15,297,000 |
